Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Propranolol in Newborns With Retinopathy of Prematurity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Infants who have been screened for ROP (≤ 32 weeks gestation) who develop Stage 2 ROP in zone II without plus.~2. Informed Consent from a parent~Exclusion Criteria:~1. Newborns with one or more of the following conditions at the enrollment in the study:~   * Heart failure.~  * Recurrent episodes of bradycardia (Heart rate less than 90 bpm).~  * Atrio-ventricular block (second or third degree).~  * Significant congenital heart anomaly, not including patent ductus arteriosus, patent foramen ovale or small ventricular septal defect.~  * Hypotension.~  * Renal failure.~  * Cerebral hemorrhage.~  * Other diseases which contraindicate the use of beta-blockers~2. Newborns with ROP stages more advances than Stage 2 in zone II without plus.~3. Informed Consent from a parent refused. This will mean that an infant automatically will receive standard laser therapy. No data will be used from an infant without Informed Consent.

- Gender: ALL
- Minimum Age: 22 Weeks
- Maximum Age: 32 Weeks
- Healthy Volunteers: f

Study Arms:
- Propranolol (Type: EXPERIMENTAL): Oral Propranolol administration is the experimental arm of this study
- Control (Type: NO_INTERVENTION): Control arm is treated following the standard treatment schedule of Early Treatment For Retinopathy Of Prematurity Cooperative Group

Based on this trial design, predict the completion outcome and termination type (if applicable).